Revisiting the Fast Rise of Crispr
What’s the biggest invention of the past five or 10 years? I would pick the gene-editing technology known as Crispr-Cas9. Because it gives scientists an easy way to fix mutations and activate dormant genes, Crispr has already helped them better understand the links between genetics and disease and opened the door to precise gene-therapy treatments. It’s also raising the prospect of genetically modified crops and livestock that don’t borrow genes from other species. It’s no wonder that dozens of startups are racing to harness Crispr and related technologies.
But how far should we take it, and how fast? Should we edit human embryos to remove deleterious traits, and while, we’re at it, put in some beneficial ones? The prospect is real—and already troubling even some of the early developers of the technology.
Revisiting MIT Technology Review’s top Crispr-related stories from the past two years, I was struck by how quickly the technology has reshaped biotechnology and attracted hundreds of millions of dollars of venture capital. Will it soon revolutionize medical practice as well?
Innovator Under 35: Feng Zhang, August 2013, by David Rotman
Genome Surgery, February 2014, by Susan Young
Genome Editing: the Experiment and the Impact, April 2014, by Christina Larson and Amanda Schaffer
On the Horns of the GMO Dilemma, September 2014, and A Potato Made with Gene Editing, April 2015, by Antonio Regalado
Who Owns the Biggest Biotech Discovery of the Century?, December 2014, by Antonio Regalado
Engineering the Perfect Baby, March 2015, by Antonio Regalado
Genome Gambits, April 2015, by Jennifer A. Doudna
Keep Reading
Most Popular
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.